Sphingosine kinase 1 inhibitors for modulating the production of sphingosine-1-phosphate (S1P)—a potential treatment of cancer, sickle cell disease, atherosclerosis, asthma, diabetes, and fibrosis. Here, SPHK1 is linked to atherosclerosis.